Recent studies have shown that PKM2 knockdown does not prohibit bladder cancer development but impairs HRas‐driven tumor growth and maintenance by suppressing vascular endothelial growth factor (VEGF)‐related angiogenesis by reducing PKM2 and signal transducer and activator of transcription 3 (STAT3) complex formation and nuclear translocation. The gene discussed is VEGFA; the disease is urinary bladder cancer.